Arvinas, Inc. (ARVN)
7.67
-0.12
(-1.54%)
USD |
NASDAQ |
Sep 25, 09:57
Arvinas Research and Development Expense (Quarterly) : 52.30M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 52.30M |
| March 31, 2026 | 60.00M |
| December 31, 2025 | 59.80M |
| September 30, 2025 | 64.30M |
| June 30, 2025 | 68.00M |
| March 31, 2025 | 90.80M |
| December 31, 2024 | 83.30M |
| September 30, 2024 | 86.90M |
| June 30, 2024 | 93.70M |
| March 31, 2024 | 84.30M |
| December 31, 2023 | 95.20M |
| September 30, 2023 | 85.90M |
| June 30, 2023 | 103.40M |
| March 31, 2023 | 95.30M |
| December 31, 2022 | 98.30M |
| September 30, 2022 | 77.50M |
| June 30, 2022 | 75.30M |
| March 31, 2022 | 64.00M |
| December 31, 2021 | 61.80M |
| Date | Value |
|---|---|
| September 30, 2021 | 40.60M |
| June 30, 2021 | 43.01M |
| March 31, 2021 | 34.87M |
| December 31, 2020 | 33.20M |
| September 30, 2020 | 30.01M |
| June 30, 2020 | 23.42M |
| March 31, 2020 | 21.73M |
| December 31, 2019 | 20.41M |
| September 30, 2019 | 16.59M |
| June 30, 2019 | 16.00M |
| March 31, 2019 | 14.19M |
| December 31, 2018 | 14.56M |
| September 30, 2018 | 13.15M |
| June 30, 2018 | 10.34M |
| March 31, 2018 | 7.144M |
| December 31, 2017 | 6.690M |
| September 30, 2017 | 7.223M |
| June 30, 2017 | 7.824M |
| March 31, 2017 | 7.056M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | 2.142M |
| CNBX Pharmaceuticals, Inc. | -- |
| GB Sciences, Inc. | -- |
| Fulcrum Therapeutics, Inc. | 12.23M |
| Definium Therapeutics, Inc. | 48.66M |